RaySearch Laboratories AB (publ) Year-end Report 2010

RaySearch Laboratories AB (publ) Year-end Report 2010

JANUARY 1 - DECEMBER 31, 2010

  · Net sales for the year amounted to SEK 117.7  M (83.7)
  · Operating profit totaled SEK 39.9 M (40.9)
  · Profit after tax totaled SEK 28.9 M (30.1) and earnings per share
amounted to SEK 0.84 (0.88)
  · Cash flow amounted to negative SEK 5.0 M (positive 9.4)
  · RaySearch received FDA clearance for RayStation® in the US in March
  · The collaboration agreement with Varian was expanded in April
  · Breakthrough RayStation® order from Massachusetts General Hospital
was received in October
  · The Board of Directors proposes a dividend of SEK 0.50 (0.50) per
share

EVENTS AFTER THE END OF THE PERIOD

  · RaySearch established a sales organization in the US in January
  · Two new RayStation® orders were announced in February

“The past year was highly successful in financial terms and in addition,
we underwent substantial strategic changes that are crucial to our
future development. The launch of our proprietary treatment planning
system RayStation® went well and the breakthrough order from
Massachusetts General Hospital was a very important milestone for
RaySearch”, says Johan Löf, CEO of RaySearch.

“We will continue building up our international sales and marketing
organization and work closely together with new and existing customers
to further refine RayStation®. We have already noted growing interest in
RayStation® following the breakthrough in the US and I am convinced that
the customer list will continue to grow in 2011”, concludes Johan Löf.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com (johan.lof@raysearchlabs.com)